Cancer despite immunosurveillance: immunoselection and immunosubversion
The DOI matches its Crossref record; 127 of the 127 references it cites were found in a registry or an index.
Abstract
Numerous innate and adaptive immune effector cells and molecules participate in the recognition and destruction of cancer cells, a process that is known as cancer immunosurveillance. But cancer cells avoid such immunosurveillance through the outgrowth of poorly immunogenic tumour-cell variants (immunoselection) and through subversion of the immune system (immunosubversion). At the early stages of carcinogenesis, cell-intrinsic barriers to tumour development seem to be associated with stimulation of an active antitumour immune response, whereas overt tumour development seems to correlate with changes in the immunogenic properties of tumour cells. The permanent success of treatments for cancer might depend on using immunogenic chemotherapy to re-establish antitumour immune responses.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cancers must escape from immunosurveillance to advance to a clinically detectable state, meaning that they either are passively selected to ''hide'' from immune recognition (immunoselection) or actively suppress immune effectors (immunosubversion).249”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [249]
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
The Pathophysiology of Mitochondrial Cell Death
Green, D. R., & Kroemer, G. (2004) · Science · doi:10.1126/science.1099320 · Cited by 3,418
Sakaguchi, S. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141122 · Cited by 3,306
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
Immunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Cited by
Items 101–200 of 1,000
The oxysterol–CXCR2 axis plays a key role in the recruitment of tumor-promoting neutrophils
Raccosta, L., Fontana, R., Maggioni, D., Lanterna, C., Villablanca, E. J., Paniccia, A., Musumeci, A., Chiricozzi, E., Trincavelli, M. L., Daniele, S., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130440 · Cited by 230
“…(Hanahan and Weinberg, 2011) as well as the ability of tumor cells to affect the tumor microenviron ment by smoldering inflammation (de Visser et al., 2006; Mantovani et al., 2008) or even taking advantage of inflammation to grow and metas tasize (Zitvogel et al., 2006; Grivennikov et al., 2010).”
Dendritic cell-based immunotherapy: a basic review and recent advances
Constantino, J., Gomes, C., Falcão, A., Neves, B. M., & Cruz, M. T. (2017) · Immunologic Research · doi:10.1007/s12026-017-8931-1 · Cited by 228
“Among these strategies, it is worth highlighting the intratumoral administration of ex vivoexpanded and not-loaded-with-AG DCs, the DC-based exosomes, and the direct administration of AGs coupled to Abs (in vivo DC targeting) already described above [12].”
BackgroundHallmarks of cancer—the new testament
Senga, S. S., & Grose, R. P. (2021) · Open Biology · doi:10.1098/rsob.200358 · Cited by 221
Eisenring, M., vom Berg, J., Kristiansen, G., Saller, E., & Becher, B. (2010) · Nature Immunology · doi:10.1038/ni.1947 · Cited by 221
“These dual opposing functions of immunity are called 'cancer immunoediting', a process that consists of three phases: elimination (also known as immunosurveillance or protection), equilibrium (persistence) and escape (progression”
BackgroundNatural Killer Cells in Human Cancer: From Biological Functions to Clinical Applications
Levy, E. M., Roberti, M. P., & Mordoh, J. (2011) · BioMed Research International · doi:10.1155/2011/676198 · Cited by 219
“CD8+ cytotoxic T cells (CTL) and NK cells are the most likely effectors for an effective antitumor immunity [31].”
BackgroundTGF-β in T Cell Biology: Implications for Cancer Immunotherapy
Dahmani, A., & Delisle, J.-S. (2018) · Cancers · doi:10.3390/cancers10060194 · Cited by 214
Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy
Song, X., Liu, C., Wang, N., Huang, H., He, S., Gong, C., & Wei, Y. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.04.010 · Cited by 212
Sharma, D., Brummel‐Ziedins, K. E., Bouchard, B. A., & Holmes, C. E. (2014) · Journal of Cellular Physiology · doi:10.1002/jcp.24539 · Cited by 212
“Tumor cells downregulate MHC class I in order to avoid antigen presentation to T cells and subsequent activation of anti-tumor cytotoxic immune responses (Zitvogel et al., 2006).”
BackgroundPolarized immune responses differentially regulate cancer development
Johansson, M., DeNardo, D. G., & Coussens, L. M. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00600.x · Cited by 209
“CD8(1) T cells were found to be particularly important and required for anti-tumor effects in several experimental mouse models (77).”
BackgroundResultGianchecchi, E., & Fierabracci, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02374 · Cited by 207
Th2‐mediated anti‐tumour immunity: friend or foe?
Ellyard, J. I., Simson, L., & Parish, C. R. (2007) · Tissue Antigens · doi:10.1111/j.1399-0039.2007.00869.x · Cited by 207
Workenhe, S. T., & Mossman, K. L. (2014) · Molecular Therapy · doi:10.1038/mt.2013.220 · Cited by 203
Ménard, C., Blay, J.-Y., Borg, C., Michiels, S., Ghiringhelli, F., Robert, C., Nonn, C., Chaput, N., Taïeb, J., Delahaye, N. F., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3807 · Cited by 202
“Indeed, tumor cell progression not only depends on cell autonomous tumor suppressive pathways but also on extrinsic immunologic barriers (10).”
BackgroundSelf-citationEcto‐calreticulin in immunogenic chemotherapy
Obeid, M., Tesniere, A., Panaretakis, T., Tufi, R., Joza, N., Van Endert, P., Ghiringhelli, F., Apetoh, L., Chaput, N., Flament, C., et al. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00567.x · Cited by 202
“In vitro, DCs pulsed with apoptotic bodies (23, 24) and exosomes from tumor cells (25) appear to be more efficient in cross-priming of CD8(1) T cells as compared with DCs exposed to lysates or other derivatives obtained from non-stressed tumor cells (26, 27).”
ResultCancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking
Conniot, J., Silva, J. M., Fernandes, J. G., Silva, L. C., Gaspar, R., Brocchini, S., Florindo, H. F., & Barata, T. S. (2014) · Frontiers in Chemistry · doi:10.3389/fchem.2014.00105 · Cited by 200
“Tumor cells have also the ability to evade cell death (Fernald and Kurokawa, 2013) and to escape immune system surveillance (Zitvogel et al., 2006).”
Backgroundvan de Water, W., Markopoulos, C., van de Velde, C. J. H., Seynaeve, C., Hasenburg, A., Rea, D., Putter, H., Nortier, J. W. R., de Craen, A. J. M., Hille, E. T. M., et al. (2012) · JAMA · doi:10.1001/jama.2012.84 · Cited by 200
“Older patients might respond differently to a tumor than younger patients.(29) In addition, older patients might respond differently to a certain therapy.”
BackgroundFucikova, J., Becht, E., Iribarren, K., Goc, J., Remark, R., Damotte, D., Alifano, M., Devi, P., Biton, J., Germain, C., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1142 · Cited by 199
“In numerous cancers, the presence of tumor-infiltrating effector memory T cells correlates with reduced metastatic invasion and increased survival of the patient (47).”
BackgroundTumor-derived exosomes induce CD8+ T cell suppressors
Maybruck, B. T., Pfannenstiel, L. W., Diaz-Montero, M., & Gastman, B. R. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0269-7 · Cited by 196
The untold story of IFN-γ in cancer biology
Kursunel, M. A., & Esendagli, G. (2016) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2016.07.005 · Cited by 192
“However, the tumor cells take the advantage of being indigenous and poorly immunogenic [8,9].”
Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancer
Prelaj, A., Tay, R., Ferrara, R., Chaput, N., Besse, B., & Califano, R. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.002 · Cited by 193
The Case of Oncolytic Viruses Versus the Immune System: Waiting on the Judgment of Solomon
Prestwich, R. J., Errington, F., Diaz, R. M., Pandha, H. S., Harrington, K. J., Melcher, A. A., & Vile, R. G. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.135 · Cited by 191
“It is certainly true that the tumor microenvironment is usually locally immunosuppressed due to tumor mechanisms of im-munosubversion (Zitvogel et al. , 2006), and therefore likely to be permissive of viral replication.”
InfluentialEnhancing Efficacy of Anticancer Vaccines by Targeted Delivery to Tumor-Draining Lymph Nodes
Jeanbart, L., Ballester, M., de Titta, A., Corthésy, P., Romero, P., Hubbell, J. A., & Swartz, M. A. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0019-t · Cited by 191
“Targeting the tdLN with nanoparticle-conjugated OVA and CpG reduces the frequencies of tumor-infiltrating MDSCs and Tregs Immunosuppressive cells, such asMDSCs and Foxp3þCD4þ Tregs, contribute to tumor-induced tolerance (34, 35) and classically hinder cancer immunotherapies, making them an important target when design…”
BackgroundMethodMontégut, L., López-Otín, C., & Kroemer, G. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02020-z · Cited by 190
Mejías, R., Pérez-Yagüe, S., Gutiérrez, L., Cabrera, L. I., Spada, R., Acedo, P., Serna, C. J., Lázaro, F. J., Villanueva, Á., Morales, M. D. P., et al. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.01.008 · Cited by 186
Aspord, C., Leccia, M.-T., Charles, J., & Plumas, J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0114-t · Cited by 187
Kucharzewska, P., & Belting, M. (2013) · Journal of Extracellular Vesicles · doi:10.3402/jev.v2i0.20304 · Cited by 186
Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy
Yang, H., Ma, Y., Chen, G., Zhou, H., Yamazaki, T., Klein, C., Pietrocola, F., Vacchelli, E., Souquere, S., Sauvat, A., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1149673 · Cited by 185
Targeting microRNAs as key modulators of tumor immune response
Paladini, L., Fabris, L., Bottai, G., Raschioni, C., Calin, G. A., & Santarpia, L. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0375-2 · Cited by 184
“In conditions of equilibrium, immune system can induce a state of functional dormancy in cells, which can evade from this form of immune-mediated latent tumor through different strategies that allow them to proliferate [26, 28–33].”
BackgroundHiraoka, N., Yamazaki–Itoh, R., Ino, Y., Mizuguchi, Y., Yamada, T., Hirohashi, S., & Kanai, Y. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.10.009 · Cited by 175
Cancer Stem Cell Immunology: Key to Understanding Tumorigenesis and Tumor Immune Escape?
Bruttel, V. S., & Wischhusen, J. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00360 · Cited by 174
“Alternatively, cancer cells may actively attenuate immunosurveillance (immunosubversion) by secretion or expression of immunosuppressive factors (11) or by recruitment of accessory cells, which locally suppress the immune system (141, 142).”
BackgroundPark, J., Yang, J., Wenzel, A. T., Ramachandran, A., Lee, W. J., Daniels, J. C., Kim, J., Martinez-Escala, E., Amankulor, N., Pro, B., et al. (2017) · Blood · doi:10.1182/blood-2017-02-768234 · Cited by 172
Epistasis between MicroRNAs 155 and 146a during T Cell-Mediated Antitumor Immunity
Huffaker, T. B., Hu, R., Runtsch, M. C., Bake, E., Chen, X., Zhao, J., Round, J. L., Baltimore, D., & O'Connell, R. M. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.10.025 · Cited by 171
“However, there remain several aspects of antitumor immunity that are unclear and appear to be governed by complex regulatory systems that have limited this application in the clinic thus far (Zitvogel et al., 2006).”
BackgroundHigh hydrostatic pressure induces immunogenic cell death in human tumor cells
Fucikova, J., Moserova, I., Truxova, I., Hermanova, I., Vancurova, I., Partlova, S., Fialova, A., Sojka, L., Cartron, P., Houska, M., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28766 · Cited by 170
“In addition to the standard treatment of metastatic disease using combinations of chemotherapeutics, it would be beneficial to patients with cancer to elicit tumor-specific immunity that would control or slow the growth of residual tumor cells.(3) Accumulating evidence indicates that cytostatic agents(4) such as anthr…”
BackgroundNecroptosis in Immuno-Oncology and Cancer Immunotherapy
Sprooten, J., De Wijngaert, P., Vanmeerbeek, I., Martin, S., Vangheluwe, P., Schlenner, S., Krysko, D. V., Parys, J. B., Bultynck, G., Vandenabeele, P., et al. (2020) · Cells · doi:10.3390/cells9081823 · Cited by 169
“, immune-checkpoints other than PD1 or CTLA4) [22,23], thus enabling deletion of T cells through prolonged exertion of immunological and metabolic exhaustion [24–26]; (III) disrupting long-term differentiation as well as perseverance of memory T lymphocytes [27,28]; and, (IV) upregulation of regulated cell death (RCD)…”
BackgroundDepression, cortisol, and suppressed cell-mediated immunity in metastatic breast cancer
Sephton, S. E., Dhabhar, F. S., Keuroghlian, A. S., Giese-Davis, J., McEwen, B. S., Ionan, A. C., & Spiegel, D. (2009) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2009.07.007 · Cited by 170
“com mised in patients for whom radiation, chemotherapy, or effects induced by the tumor itself lead to immunosuppression (Zitvogel et al., 2006).”
BackgroundTherapeutic Potential and Challenges of Natural Killer Cells in Treatment of Solid Tumors
Gras Navarro, A., Björklund, A. T., & Chekenya, M. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00202 · Cited by 167
Epardaud, M., Elpek, K. G., Rubinstein, M. P., Yonekura, A.-R., Bellemare-Pelletier, A., Bronson, R., Hamerman, J. A., Goldrath, A. W., & Turley, S. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0045 · Cited by 167
“Indeed, tumors can escape immunosurveillance by disabling the function of cytolytic lymphocytes and antigen-presenting cells, by preventing blood-borne lymphocytes from infiltrating malignant tissue or by inducing tolerance ( 1 , 7, 8).”
BackgroundWang, J., Jia, Y., Wang, N., Zhang, X., Tan, B., Zhang, G., & Cheng, Y. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-7 · Cited by 166
“Immune reaction was proposed as the seventh hallmark of cancer [5].”
BackgroundCombined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients
Zeestraten, E. C. M., Reimers, M. S., Saadatmand, S., Dekker, J.-W. T., Liefers, G. J., van den Elsen, P. J., van de Velde, C. J. H., & Kuppen, P. J. K. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.696 · Cited by 165
“Third, tumour cell immune reactivity can become suppressed by the attraction of immunosuppressive regulatory T cells (Tregs) into the tumour micro-environment (Zitvogel et al, 2006; Nosho et al, 2010).”
Chemerin/chemR23 axis in inflammation onset and resolution
Mariani, F., & Roncucci, L. (2015) · Inflammation Research · doi:10.1007/s00011-014-0792-7 · Cited by 164
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
Tang, L., Huang, Z., Mei, H., & Hu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01521-5 · Cited by 162
Yi, M., Niu, M., Zhang, J., Li, S., Zhu, S., Yan, Y., Li, N., Zhou, P., Chu, Q., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01155-6 · Cited by 163
Rouce, R. H., Shaim, H., Sekine, T., Weber, G., Ballard, B., Ku, S., Barese, C., Murali, V, Wu, M.-F., Liu, H., et al. (2016) · Leukemia · doi:10.1038/leu.2015.327 · Cited by 161
Obeid, M., Panaretakis, T., Tesniere, A., Joza, N., Tufi, R., Apetoh, L., Ghiringhelli, F., Zitvogel, L., & Kroemer, G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1622 · Cited by 161
“Driven by this consideration, we speculated that chemotherapeutic regimes that would stimulate an immune response against tumor cells should be particularly efficient (3, 4).”
BackgroundPrognostic and predictive value of DAMPs and DAMP-associated processes in cancer
Fucikova, J., Moserova, I., Urbanova, L., Bezu, L., Kepp, O., Cremer, I., Salek, C., Strnad, P., Kroemer, G., Galluzzi, L., et al. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00402 · Cited by 159
Self-citation和田, 純., Suzuki, H. Y., Fuchino, R., Yamasaki, A., Nagai, S., Yanai, K., Koga, K., Nakamura, M., Tanaka, M., Morisaki, T., et al. (2009) · PubMed · Cited by 169
Potential role of immunosenescence in cancer development
Fulop, T., Kotb, R., Fortin, C. F., Pawelec, G., de Angelis, F., & Larbi, A. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05370.x · Cited by 159
Clark, C. E., Beatty, G. L., & Vonderheide, R. H. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.09.037 · Cited by 181
“Indeed, this requirement for immune escape has even been proposed as the seventh ‘‘hallmark of cancer” [7] in addition to the six cell-intrinsic”
BackgroundNanomedicine‐Boosting Tumor Immunogenicity for Enhanced Immunotherapy
Huang, J., Yang, B., Peng, Y., Huang, J., Wong, S. H. D., Bian, L., Zhu, K., Shuai, X., & Han, S. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202011171 · Cited by 157
Current approaches in dendritic cell generation and future implications for cancer immunotherapy
Tuyaerts, S., Aerts, J. L., Corthals, J., Neyns, B., Heirman, C., Breckpot, K., Thielemans, K., & Bonehill, A. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0334-z · Cited by 156
“tumor cells (immunoediting) and suppression of the immune system [53, 205].”
DAMPs and PDT-mediated photo-oxidative stress: exploring the unknown
Garg, A. D., Krysko, D. V., Vandenabeele, P., & Agostinis, P. (2011) · Photochemical & Photobiological Sciences · doi:10.1039/c0pp00294a · Cited by 172
Pachynski, R. K., Zabel, B. A., Kohrt, H. E., Tejeda, N. M., Monnier, J., Swanson, C. D., Holzer, A. K., Gentles, A. J., Sperinde, G. V., Edalati, A., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112124 · Cited by 154
“Conversely, antitumor effector cells can arrest the development or expansion of malignancies: NK cells are important mediators of innate antitumor immunity, and immunostimulatory DCs and cytotoxic T cells participate in tumor suppression as well (Zitvogel et al., 2006).”
BackgroundHeterojunction engineered bioactive chlorella for cascade promoted cancer therapy
Ou, M., Lin, C., Wang, Y., Lu, Y., Wang, W., Li, Z., Zeng, W., Zeng, X., Ji, X., & Mei, L. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.059 · Cited by 152
Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
Simpson, R. C., Shanahan, E. R., Scolyer, R. A., & Long, G. V. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00803-9 · Cited by 153
Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma
Thompson, J. F., Agarwala, S. S., Smithers, B. M., Ross, M. I., Scoggins, C. R., Coventry, B. J., Neuhaus, S. J., Minor, D. R., Singer, J. M., & Wachter, E. A. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4169-5 · Cited by 152
Zumwalt, T. J., Arnold, M., Goel, A., & Boland, C. R. (2015) · Oncotarget · doi:10.18632/oncotarget.3205 · Cited by 151
“Escape from immune detection leads to tumor metastasis [25].”
BackgroundRegulatory T cells in the bone marrow microenvironment in patients with prostate cancer
Zhao, E., Wang, L., Dai, J., Kryczek, I., Wei, S., Vatan, L., Altuwaijri, S., Sparwasser, T. D., Wang, G., Keller, E. T., et al. (2012) · OncoImmunology · doi:10.4161/onci.1.2.18480 · Cited by 170
Effects of vitamin B6 metabolism on oncogenesis, tumor progression and therapeutic responses
Galluzzi, L., Vacchelli, E., Michels, J., Garcia, P., Kepp, O., Senovilla, L., Vitale, I., & Kroemer, G. (2013) · Oncogene · doi:10.1038/onc.2012.623 · Cited by 150
Watanabe, Y., Katou, F., Ohtani, H., Nakayama, T., Yoshie, O., & Hashimoto, K. (2010) · Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology · doi:10.1016/j.tripleo.2009.12.015 · Cited by 168
Beaugerie, L., Carrat, F., Colombel, J., Bouvier, A., Sokol, H., Babouri, A., Carbonnel, F., Laharie, D., Faucheron, J., Simon, T., et al. (2013) · Gut · doi:10.1136/gutjnl-2013-305763 · Cited by 149
Trial watch: Dendritic cell-based interventions for cancer therapy
Galluzzi, L., Senovilla, L., Vacchelli, E., Eggermont, A. M. M., Fridman, W. H., Galon, J., Sautès‐Fridman, C., Tartour, É., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.21494 · Cited by 173
The effect of physical exercise on anticancer immunity
Fiuza‐Luces, C., Valenzuela, P. L., Gálvez, B. G., Ramírez, M. R., López‐Soto, A., Simpson, R. J., & Lucía, A. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00943-0 · Cited by 178
Asano, J., Watanabe, T., Oguchi, T., Kanai, K., Maruyama, M., Ito, T., Muraki, T., Hamano, H., Arakura, N., Matsumoto, A., et al. (2015) · The Journal of Rheumatology · doi:10.3899/jrheum.150436 · Cited by 153
ER stress affects processing of MHC class I-associated peptides
Granados, D. P., Tanguay, P.-L., Hardy, M.-P., Caron, É., de Verteuil, D., Meloche, S., & Perreault, C. (2009) · BMC Immunology · doi:10.1186/1471-2172-10-10 · Cited by 146
“Background The ultimate role of the immune system in host defense is to eliminate infected and transformed cells [1,2].”
BackgroundCatenacci, D. V. T. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2014.09.011 · Cited by 144
“(Devaud et al., 2013; Gimbrone et al., 1972; Kakarla et al., 2012; Bellou et al., 2013; Mueller and Fusenig, 2004; Zitvogel et al., 2006) Over the last decades, the premise of using molecularly targeted agents for targeted patient populations based on tumor/stromal molecular profiles and pathway…”
BackgroundAnticancer metal drugs and immunogenic cell death
Terenzi, A., Pirker, C., Keppler, B. K., & Berger, W. (2016) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2016.06.021 · Cited by 151
Targeting tumors with peptides from natural sources
Bhutia, S. K., & Maiti, T. K. (2008) · Trends in biotechnology · doi:10.1016/j.tibtech.2008.01.002 · Cited by 157
Chemotherapeutic Targeting of Cancer-Induced Immunosuppressive Cells
Alizadeh, D., & Larmonier, N. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0301 · Cited by 142
“Multiple mechanisms of cancer immune evasion and immunoinhibitory pathways have been identified (3).”
Zhao, R., Song, Y., Wang, Y., Huang, Y., Li, Z., Cui, Y., Yi, M., Xia, L., Zhuang, W., Wu, X., et al. (2019) · Cell Proliferation · doi:10.1111/cpr.12571 · Cited by 161
Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy
Liu, Z., Shi, M., Ren, Y., Xu, H., Weng, S., Ning, W., Ge, X., Liu, L., Guo, C., Duo, M., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01738-6 · Cited by 176
Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists
Peggs, K. S., Quezada, S. A., & Allison, J. P. (2009) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2009.03912.x · Cited by 141
Oncolysis without viruses — inducing systemic anticancer immune responses with local therapies
Kepp, O., Marabelle, A., Zitvogel, L., & Kroemer, G. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0272-7 · Cited by 154
Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set
Sukkurwala, A. Q., Adjemian, S., Senovilla, L., Michaud, M., Spaggiari, S., Vacchelli, E., Baracco, E. E., Galluzzi, L., Zitvogel, L., Kepp, O., et al. (2014) · OncoImmunology · doi:10.4161/onci.28473 · Cited by 140
“Next, we tested MCA205 cells exposed to hedamycin, septacidin, and sangivamycin for (1) CRT surface exposure, by immunofluorescence in conjunction with cytofluorometry (Fig.”
BackgroundMethodMicroenvironmental regulation of cancer metastasis by miRNAs
Zhang, Y., Yang, P., & Wang, X. (2013) · Trends in Cell Biology · doi:10.1016/j.tcb.2013.09.007 · Cited by 147
Immune evasion of microsatellite unstable colorectal cancers
Kloor, M., Michel, S., & von Knebel Doeberitz, M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25283 · Cited by 138
“This phenomenon is referred to as immune subversion.(82)”
BackgroundmiR-25/93 mediates hypoxia-induced immunosuppression by repressing cGAS
Wu, M.-Z., Cheng, W.-C., Chen, S.-F., Nieh, S., O’Connor, C., Liu, C.-L., Tsai, W.-W., Wu, C.-J., Martin, L., Lin, Y.-S., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3615 · Cited by 138
“Cancer cells can escape both innate and adaptive immune responses by deregulating immune effector cells and immunosuppressive cells, as well as molecules responsible for cancer cell recognition and elimination 2 .”
A Believer’s Overview of Cancer Immunosurveillance and Immunotherapy
Finn, O. J. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701302 · Cited by 138
“The conundrum that arose when tumor Ags were identified and antitumor humoral and cellular immunity confirmed was why and how the tumor escapes and would an antitumor immune response ever be a tumor rejection response (68).”
BackgroundYao, W., He, J., Yang, Y., Wang, J., Qian, Y., Yang, T., & Ji, L. (2017) · Scientific Reports · doi:10.1038/s41598-017-08128-1 · Cited by 152
Human Basal Cell Carcinoma Is Associated with Foxp3+ T cells in a Th2 Dominant Microenvironment
Kaporis, H. G., Guttman‐Yassky, E., Lowes, M. A., Haider, A. S., Fuentes‐Duculan, J., Darabi, K., Whynot, J. A., Khatcherian, A., Cardinale, I. R., Novitskaya, I., et al. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700884 · Cited by 140
Chmielewski, M. M., & Abken, H. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1202-z · Cited by 157
Reig, M., Darnell, A., Forner, A., Rimola, J., Ayuso, C., & Bruix, J. (2014) · Seminars in Liver Disease · doi:10.1055/s-0034-1394143 · Cited by 149
CpG Oligonucleotides as Cancer Vaccine Adjuvants
Shirota, H., Tross, D., & Klinman, D. M. (2015) · Vaccines · doi:10.3390/vaccines3020390 · Cited by 143
“The microenvironment in which tumors reside is rich in factors that support growth and contains Tregs and MDSCs that down-regulate tumor-specific immunity [98,99].”
BackgroundGao, K., Li, X., Zhang, L., Bai, L., Dong, W., Gao, K., Shi, G., Xia, X., Wu, L., & Zhang, L. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.03.002 · Cited by 135
“CD8 T cells and NK cells are the most likely effector cells for establishing antitumor immunity [31–33].”
BackgroundRole of Altered Expression of HLA Class I Molecules in Cancer Progression
Aptsiauri, N., Cabrera, T., Méndez, R., Garcia-Lor, A., Ruiz‐Cabello, F., & Garrido, F. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-72005-0_13 · Cited by 132
“The process that involves the recognition and destruction of cancer cells by numerous innate and adaptive immune effector cells and molecules is known as immunosurveillance (Garrido et al. 1997; Zitvogel et al. 2006; Smyth et al. 2006).”
BackgroundHepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment
Owusu, B., Galemmo, R., Janetka, J., & Klampfer, L. (2017) · Cancers · doi:10.3390/cancers9040035 · Cited by 130
Bourrier, A., Carrat, F., Colombel, J., Bouvier, A., Abitbol, V., Marteau, P. R., Cosnes, J., Simon, T., Peyrin‐Biroulet, L., Beaugerie, L., et al. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13466 · Cited by 130
“23 The theoretical general mechanisms by which thiopurines could promote the appearance of de novo cancers, or accelerate growth of a pre-existing cancer, are mutations of cell DNA(24) and impaired number and/or function of immune cells that prevent cell proliferation.(25) Thiopurines can also promote the proliferatio…”
BackgroundCarretero, R., Romero, J. M., Ruiz-Cabello, F., Maleno, I., Rodriguez, F., Camacho, F. M., Real, L. M., Garrido, F., & Cabrera, T. (2008) · Immunogenetics · doi:10.1007/s00251-008-0303-5 · Cited by 128
“It has been proposed that the main contributor to the emergence of these tumor clones with MHC class I altered expression is T cell immunoselection (Garcia-Lora et al. 2002; Zitvogel et al. 2006).”
BackgroundMacrophages in the embryo and beyond: Much more than just giant phagocytes
Ovchinnikov, D. A. (2008) · genesis · doi:10.1002/dvg.20417 · Cited by 128
“…M2-polarized TAMs secrete anti-inflammatory cytokines, e.g., IL-10, and not only fail to elicit and sustain an immune response to tumor cells, but actually suppress the ability of other immune cells, such as natural killer (NK) and T cells, to do so (Mantovani et al., 2005; Zitvogel et al., 2006).”
BackgroundAramillo Irizar, P., Schäuble, S., Esser, D., Groth, M., Frahm, C., Priebe, S., Baumgart, M., Hartmann, N., Marthandan, S., Menzel, U., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02395-2 · Cited by 127
NK cell exhaustion in the tumor microenvironment
Hao, J., Yang, H., Xiong, H., & Luo, K. Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1303605 · Cited by 160
Genotyping and Expression Analysis of IDO2 in Human Pancreatic Cancer: A Novel, Active Target
Witkiewicz, A. K., Costantino, C. L., Metz, R., Muller, A. J., Prendergast, G. C., Yeo, C. J., & Brody, J. R. (2009) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2008.12.018 · Cited by 127
“Recently, several lines of research are converging to suggest that the immune system is important for tumor surveillance and in certain instances tumor killing (4).”
BackgroundLiu, J., Zhang, S., Hu, Y., Yang, Z., Li, J., Liu, X., Deng, L., Wang, Y., Zhang, X., Jiang, T., et al. (2016) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000122 · Cited by 124
Miao, H., Choi, B. D., Suryadevara, C. M., Sanchez-Perez, L., Yang, S., De Leon, G., Sayour, E. J., McLendon, R., Herndon, J. E., Healy, P., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094281 · Cited by 124
“expanded tumor-infiltrating lymphocytes (TILs) [8] and T-cell receptor (TCR) gene therapy [9,10].”
BackgroundImmunosurveillance in clinical cancer management
Kroemer, G., Chan, T. A., Eggermont, A. M. M., & Galluzzi, L. (2024) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21818 · Cited by 123
“5,6 9 ICIs have indeed been designed to activate T lymphocytes by interrupting inhibitory signals delivered by various receptors, including programmed cell death 1 (PD ‐ 1), cytotoxic T lymphocyte ‐ associated protein 4 (CTLA ‐ 4), and lymphocyte ‐ activation gene 3 (LAG ‐ 3), among others.”
BackgroundTumor-Associated Lymphatic Vessel Features and Immunomodulatory Functions
Garnier, L., Gkountidi, A.-O., & Hugues, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00720 · Cited by 120
In vivo imaging of T cell delivery to tumors after adoptive transfer therapy
Pittet, M. J., Grimm, J., Berger, C. R., Tamura, T., Wojtkiewicz, G., Nahrendorf, M., Romero, P., Swirski, F. K., & Weissleder, R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704460104 · Cited by 121
Neutrophil activation and survival are modulated by interaction with NK cells
Costantini, C., Micheletti, A., Calzetti, F., Perbellini, O., Pizzolo, G., & Cassatella, M. A. (2010) · International Immunology · doi:10.1093/intimm/dxq434 · Cited by 140
Wang, L., Kumar, S., Dahiya, S., Wang, F., Wu, J., Newick, K., Han, R., Samanta, A., Beier, U. H., Akimova, T., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.10.018 · Cited by 120
“Tumors have distinctive properties of growth, invasion andmetastasis (Hanahan and Weinberg, 2000), and the ability to evade immune destruction (Zitvogel et al., 2006).”
Park, M. H., Lee, J. S., & Yoon, J. H. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.23095 · Cited by 121
Axelrad, J. E., Bernheim, O. E., Colombel, J., Malerba, S., Ananthakrishnan, A. N., Yajnik, V., Hoffman, G., Agrawal, M., Lukin, D. J., Desai, A. P., et al. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.07.037 · Cited by 121
Metadata
- Authors
- Zitvogel, L., Tesniere, A., & Kroemer, G.
- Affiliations
- Inserm (FR)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Kroemer, Guido
- Venue
- Nature reviews. Immunology
- Published
- 2006-09-15
- Volume
- 6
- Issue
- 10
- Pages
- 715-727
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2063192133
- Cited by
- 1,324
- References
- 127
- Citations by year
- 2026: 15 · 2025: 26 · 2024: 62 · 2023: 75 · 2022: 68 · 2021: 63 · 2020: 63 · 2019: 60 · 2018: 66 · 2017: 76 · 2016: 72 · 2015: 81 · 2014: 87 · 2013: 89 · 2012: 82
- FWCI
- 5.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Commission
- Conseil Régional, Île-de-France
- Institut National Du Cancer
- Cancéropôle Ile de France
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tumor surveillance, immunoselection, tumor immunogenicity, antitumor immunity, carcinogenesis, immunogenic chemotherapy
- MeSH terms
- Animals, Humans, Immune Tolerance, Immunologic Surveillance, Neoplasms, T-Lymphocytes, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.